Company news

Protara Therapeutics, Inc. news in 2023

Protara Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology

November 29, 2023

Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

November 2, 2023

Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

October 22, 2023

Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ

September 19, 2023

Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 4, 2023

Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

August 2, 2023

Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ

May 14, 2023

Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update

May 3, 2023

Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

May 1, 2023

Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development

April 27, 2023

Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 7, 2023

Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

February 1, 2023

Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer

January 29, 2023

Decks in 2023